BlossomHill Therapeutics, Inc. (BLSM) Stock

Healthcare · Biotechnology · Member of Other US Stocks

BlossomHill Therapeutics, Inc. (BLSM) closed at USD 14.40 on 2026-10-20, a change of -10 % over the past year, with a market capitalization of USD 495.84M.

BlossomHill Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BlossomHill Therapeutics, Inc. key figures

Previous close

USD 14.40 (2026-10-20)

1-year change

-10 %

Market cap

USD 495.84M

Enterprise value

USD 680.66M

P/E ratio (trailing)

-3.32

P/E ratio (forward)

-3.95

EPS (trailing)

-4.70

EPS (forward)

-3.95

PEG ratio

n/a

Price to book

-0.25

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.11

Employees

69

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BlossomHill Therapeutics, Inc. and compare it with other stocks.